Method for determining sensitivity to simultaneous inhibitor against parp and tankyrase

Abstract

The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.

1 .- 17 . (canceled) 
     
     
         18 . A kit for determining susceptibility to a simultaneous inhibitor against PARP (Poly ADP Ribose Polymerase) and Tankyrase, the kit comprising:
 (a) a primer or a probe that specifically binds to a nucleotide sequence encoding a p53 gene; and   (b) a primer or a probe that specifically binds to a nucleotide sequence encoding an LIG4 (DNA ligase 4).   
     
     
         19 . The kit according to  claim 18 , wherein the nucleotide sequence encoding the p53 gene is represented by SEQ ID NO: 1. 
     
     
         20 . The kit according to  claim 18 , wherein the nucleotide sequence encoding the LIG4 is represented by SEQ ID NO: 2. 
     
     
         21 . The kit according to  claim 18 , wherein the kit is the kit for DNA sequencing, Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP), Random Amplified Polymorphic Detection (RAPD), Amplified Fragment Length Polymorphism Detection (AFLPD) or DNA microarray. 
     
     
         22 . The kit according to  claim 18 , wherein the nucleotide sequence encoding an LIG4 is one or more sequence variants selected from the group consisting of a substitution of cytosine to thymine at position 8, a substitution of cytosine to thymine at position 26, a substitution of guanine to adenine at position 833 and a substitution of thymine to cytosine at position 1704 of SEQ ID NO: 2. 
     
     
         23 . The kit according to  claim 18 , wherein the LIG4 is one or more sequence variants selected from the group consisting of a substitution of alanine to valine at position 3, a substitution of threonine to isoleucine at position 9, a substitution of arginine to histidine at position 278 and a substitution of thymine of aspartic acid (GAT) to cytosine at position 568 of SEQ ID NO: 3. 
     
     
         24 . The kit according to  claim 18 , wherein the simultaneous inhibitor against PARP (Poly ADP Ribose Polymerase) and Tankyrase comprises 8-[(dimethylamino)methyl]-10-ethoxy-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5(6H)-one or 6-{4-[(5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl]piperazin-1-yl}nicotinonitrile. 
     
     
         25 . The kit according to  claim 18 , wherein the primer that specifically binds to a nucleotide sequence encoding an LIG4 is one primer pair selected from the group consisting of a primer pair represented by SEQ ID NO: 8 and 9; a primer pair represented by SEQ ID NO: 10 and 11; and a primer pair represented by SEQ ID NO: 12 and 13.